RHT - Resonance Health

[greggles]

Had a fairly steep retracement since earlier in the week but minimal Volume …… Wide ranging high Volume spikes are hard to pick …… bit more dust to settle perhaps.

No further announcements have been made by RHT since my last post but the trend is definitely up. The share price is up another 29.09% to 7.1c so far today. Volume, while nowhere near as high as it was last Monday, it still well above average. Buyers appear hungry for shares but they are having to chase the sellers for them at the moment.

 

[barney]

Buyers appear hungry for shares but they are having to chase the sellers for them at the moment.

Looks like its off to the races now!!

 

[MrChow]

Given their superior product generates very little clinical use revenue I don't really understand why the company's value has tripled because of FDA approval when TGA and CE approval was given without anyone caring mid-year.

Given it's one of the most popular stocks discussed at the other place with all the characteristics of a pump and dump how else do people think this is going to end?

Have a look at LBT or Respiri for prior examples.

 

[greggles]

Given their superior product generates very little clinical use revenue I don't really understand why the company's value has tripled because of FDA approval when TGA and CE approval was given without anyone caring mid-year.

Given it's one of the most popular stocks discussed at the other place with all the characteristics of a pump and dump how else do people think this is going to end?

Have a look at LBT or Respiri for prior examples.

It's up another 14.47% today and has had a great run this month. While I'm always skeptical of any stock that's being pumped on the website that you refer to, I have to wonder why there isn't more selling into the frenzied buying that's going on, especially given the amount of volume that's been turned over in the last week and a half. It still appears to me that buyers are chasing the sellers and there isn't much supply which seems odd given that the share price has risen more than 300% since 3 December.

 

[barney]

Given their superior product generates very little clinical use revenue I don't really understand why the company's value has tripled because of FDA approval when TGA and CE approval was given without anyone caring mid-year.

Given it's one of the most popular stocks discussed at the other place with all the characteristics of a pump and dump how else do people think this is going to end?

Have a look at LBT or Respiri for prior examples.

Hard to know where it will end Mr C.

Chart is getting steep … up another 18% today and still trading near the daily high on $4 million turnover, so there are plenty of fresh punters getting involved.

Still a relatively small Market Cap with no debt and cash flow positive (small profit) … recent R and D grant.

Don't hold but if I did, I would probably be taking something off the table either at today's close or tomorrows open, then see how the Price behaves over the next few days.

PS As I typed … current up 22% today …… The roof is starting to get hotter

 

[MrChow]

-50% fall starting the day after we posted.

 

[barney]

Don't hold but if I did, I would probably be taking something off the table either at today's close or tomorrows open

It appears that was the time to take some profit it seems …

If the fundamentals have some foundation, there should be at least another leg up after the dust settles on this retracement ….. Looking for accumulation and price stability

 

[greggles]

-50% fall starting the day after we posted.

Resonance Health is having another run today following this morning's announcement that the company has executed a non-exclusive license agreement with Wisconsin Alumni Research Foundation (WARF) for the use of numerous patents owned by WARF in the development and commercialization of new and/or alternative methods for measuring proton density fat fraction (PDFF) from MRI images.

No dollar figures are mentioned in the announcement but it's reasonable to assume that WARF would not be licensing their patents without the expectation of a return, so presumably they have done their due diligence on RHT and are confident in their ability to monetise WARF's technology.

Overall, a solid announcement that has resulted in a 42.6% share price gain for RHT today. It is currently trading just off its high for the day at 8.7c.

 

[exberliner1]

2nd biggest riser on the ASX today up 41% to 17c and closed at the day;s high with 437k bid at 17c when the auction finished.

Looking good for more of the same tomorrow imo, with news it could go anywhere

 

[Swervin Mervin]

I bought some RHT last week as I saw someone had tipped them in the CY20 tipping comp. The trend has definitely continued since the last post on ASF in April with a large volume surge through December. Looks like a nice little under the radar stock with not much fanfare and a good little unique tech that is rapidly gaining traction. After investigating a bit I found they have quite a few scientists working on a number of potential products so thanks for the heads up and lets hope the trend continues.

 

[Dona Ferentes]

I bought some RHT last week as I saw someone had tipped them in the CY20 tipping comp. The trend has definitely continued since the last post on ASF in April with a large volume surge through December. Looks like a nice little under the radar stock with not much fanfare and a good little unique tech that is rapidly gaining traction. After investigating a bit I found they have quite a few scientists working on a number of potential products so thanks for the heads up and lets hope the trend continues.

picked that one !!

I wonder if Covid-19 is having an effect on work load and referrals?

 

[Dona Ferentes]

Resonance has received Therapeutic Goods Administration approval for its flagship automated software that assesses liver fat for people with non-alcoholic fatty liver disease (NAFLD).

The approval will now allow the company to distribute the HepaFat-AI software throughout Australia. It already secured approval from the US Food and Drug Administration back in December.

Resonance says that HepaFat AI is the only approved imaging technology capable of measuring a patient’s liver fat in a way that’s “substantially equivalent” to a specialist’s assessment from a liver biopsy.

There’s a strong tailwind blowing for Resonance’s product, as non-alcoholic fatty liver disease – which is correlated to obesity – is reported the leading cause of liver disease, affecting an estimated 2.3 billion people globally. It’s believed that over the next 10 years healthcare costs associated with the disease will exceed US$1 trillion in the US and €334 billion in Europe.

HepaFat AI has already been validated and standardised for all the major MRI scanner makes and models.

 

[Dona Ferentes]

as non-alcoholic fatty liver disease – which is correlated to obesity – is reported the leading cause of liver disease....

I am interested in this topic as I am a person who travelled this route, a few years ago.
Following a trigger event, I became quite unwell and put on 10kg quite quickly. I knew I was off colour, feeling bloated and lethargic; a visit to the GP and he quickly got a diagnosis of fatty liver and also pre-diabetic. I can't remember the tests taken (just some bloods?) and as it was, the GP is a 'holistic practitioner' (in the best sense). Intervention was dietary, essentially the Michael Mosley 8 Week Blood Sugar Diet , plus a few doses ingesting a strong and ultra-pure Olive Oil. It worked; I dropped from 92kg to 82kg in two weeks (before, I was more along the lines of 85-86Kg). and there I have stayed for several years. No sign of diabetes, either.

Then the melanomas emerged. Noticed the first one, had it tested then excised. A second one on my back also developed. Surgery (think of a kebab cube, my OCD mate said) for a biopsy and removal, and the dermo said I dodged a bullet, it still being flatline but starting to burrow; at 0.8mm, (the lymphoctes are usually about 1mm down).

What has piqued my interest (as a complete layperson) is the Race Oncology (RAC) drug Bisantrene and research into proteins, and what are, to me at least, some linkages between obesity and potential cancers.

Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race Oncology is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

Health is Wealth.